A multicenter prospective study of 515 febrile neutropenia episodes in Argentina during a 5-year period

English version

Autoři: Roberto L. Parodi ^aff001; Mariana Lagrutta ^aff001; Mauro Tortolo ^aff001; Estefanía Navall ^aff001; María S. Rodríguez ^aff001; Gervasio F. Sasia ^aff001; Lucas F. De Candia ^aff001; Matias A. Gruvman ^aff001; Oscar Bottasso ^aff004; Alcides A. Greca ^aff001
Působiště autorů: 1º Cátedra de Clínica Médica y Terapéutica, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, Santa Fe, Argentina ^aff001; Servicio de Clínica Médica, Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina ^aff002; Servicio de Clínica Médica, Hospital Provincial de Rosario, Rosario, Santa Fe, Argentina ^aff003; Instituto de Inmunología Clínica y Experimental de Rosario, Universidad Nacional de Rosario, Consejo Nacional de Investigaciones Científicas y Técnicas, Rosario, Santa Fe, Argentina ^aff004
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pone.0224299

Souhrn

For better management of patients with febrile neutropenia, our study investigated the epidemiologic, microbiologic, and clinical characteristics of adult inpatients with febrile neutropenia and their mortality-associated factors. To this end, we carried out a prospective, observational, multicenter study in 28 Argentinian hospitals between 2007 and 2012. We included 515 episodes of febrile neutropenia from 346 patients, median age 49 years. Neutropenia followed chemotherapy in 77% of cases, half of the cases due to hematological malignancies. Most episodes were classified as high-risk according to MASCC criteria, and 53.6% of patients were already hospitalized at the onset of febrile neutropenia. Bloodstream infections were detected in 14% episodes; whereas an infectious source of fever was identified in 80% of cases. Mortality rate achieved to 14.95%. The binary regression analysis showed that persistence of fever at day 7, or neutropenia at day 14, dehydration and tachycardia at the onset of febrile neutropenia as well as prior infections were significantly associated with mortality. In addition to expanding our current knowledge on the features of adult patients with febrile neutropenia, present findings provide useful information for better management of them in Argentina, given the appropriate representativeness of centers participating in the study.

Klíčová slova:

Death rates – Blood – Fevers – Neutrophils – Gram negative bacteria – Neutropenia – Gram positive bacteria – Clinical microbiology

Zdroje

1. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004; 100: 228–37. doi: 10.1002/cncr.11882 14716755

2. Jacobson MA, Liu RC, Davies D, Cohen PT. Human immunodeficiency virus disease-related neutropenia and the risk of hospitalization for bacterial infection. Arch Intern Med. 1997; 157: 1825–31. 9290541

3. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002; 34: 730–51. doi: 10.1086/339215 11850858

4. Kurtin S. Myeloid toxicity of cancer treatment. J Adv Pract Oncol. 2012; 3: 209–24. 25031949

5. Sociedad Argentina De Infectologia. Guías de recomendaciones sobre diagnóstico, tratamiento y prevención de infecciones en pacientes con cáncer 2013. Rev. argent. microbiol. [online]. 2014;46, suppl.1:7–144.

6. Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis. 2005; 40 Suppl 4: S240–5.

7. Kruger P, Saffarzadeh M, Weber AN, Rieber N, Radsak M, von Bernuth H, et al. Neutrophils: Between host defence, immune modulation, and tissue injury. PLoS Pathog. 2015; 11: e1004651. doi: 10.1371/journal.ppat.1004651 25764063

8. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011; 52: e56–93. doi: 10.1093/cid/cir073 21258094

9. Viscoli C; EORTC International Antimicrobial Therapy Group. Management of infection in cancer patients. Studies of the EORTC International Antimicrobial Therapy Group (IATG). Eur J Cancer. 2002; 38 Suppl 4: S82–7.

10. de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F; ESMO Guidelines Working Group. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2010; 21 Suppl 5: v252–6.

11. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000; 18: 3038–51. doi: 10.1200/JCO.2000.18.16.3038 10944139

12. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649–55. 7165009

13. Sørensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer. 1993; 67: 773–5. doi: 10.1038/bjc.1993.140 8471434

14. Innes H, Lim SL, Hall A, Chan SY, Bhalla N, Marshall E. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer. 2008; 16: 485–91. doi: 10.1007/s00520-007-0334-8 17899215

15. Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer. 2013; 21: 1487–95 doi: 10.1007/s00520-013-1758-y 23443617

16. Uys A, Rapoport BL, Anderson R. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer. 2004; 12: 555–60. doi: 10.1007/s00520-004-0614-5 15197637

17. Carmona-Bayonas A, Gómez J, González-Billalabeitia E, Canteras M, Navarrete A, Gonzálvez ML, et al. Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients. Br J Cancer. 2011; 105: 612–7. doi: 10.1038/bjc.2011.284 21811253

18. Chan A, Verma S, Loibl S, Crawford J, Choi MR, Dreiling L, et al. Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. Crit Rev Oncol Hematol. 2012; 81:136–50. doi: 10.1016/j.critrevonc.2011.03.003 21507676

19. Gómez Roca C, Rivero M, Hugo K, Novillo A, Marta Lapadula M, Recondo G, et al. Factores de mal pronóstico en pacientes internados con neutropenia al inicio del episodio febril. M. Medicina (B Aires). 2006; 66:385–91.

20. Jin J, Lee YM, Ding Y, Koh LP, Lim SE, Lim R, et al. Prospective audit of febrile neutropenia management at a tertiary university hospital in Singapore. Ann Acad Med Singapore. 2010; 39:453–9. 20625621

21. Rabagliati B R, Fuentes L G, Orellana U E, Oporto C J, Domínguez M I, Benítez G R, et al. Etiología de episodios de neutropenia febril en pacientes adultos con cáncer hematológico y de órganos sólidos en el Hospital Clínico Universidad Católica, Santiago-Chile. Rev Chilena Infectol. 2009; 26:106–13. 19621141

22. Rabagliati R, Bertín P, Cerón I, Rojas H, Domínguez I, Vera Á, et al. Epidemiología de neutropenia febril en pacientes adultos con leucemia aguda y linfoma. Estudio de cohorte en hospitales público y privado de Santiago, Chile. Cruz R. Rev Chilena Infectol. 2014; 31:721–8.

23. Sacar S, Hacioglu SK, Keskin A, Turgut H. Evaluation of febrile neutropenic attacks in a tertiary care medical center in Turkey. J Infect Dev Ctries. 2008; 2:359–63. 19745503

24. Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, et. al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007; 30 Suppl 1: S51–9.

25. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol. 1992; 10: 316–22. doi: 10.1200/JCO.1992.10.2.316 1732432

26. Lyman GH, Kuderer NM, Crawford J, Wolff DA, Culakova E, Poniewierski MS, et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer. 2011; 117: 1917–27. doi: 10.1002/cncr.25691 21509769

27. Kamana M, Escalante C, Mullen CA, Frisbee-Hume S, Rolston KV. Bacterial infections in low-risk, febrile neutropenic patients. Cancer. 2005; 104:422–6. doi: 10.1002/cncr.21144 15937905

28. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med. 1988; 148: 2561–8. 3196123

29. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982; 72: 101–11. doi: 10.1016/0002-9343(82)90594-0 7058815

30. Kanafani ZA, Dakdouki GK, El-Chammas KI, Eid S, Araj GF, Kanj SS. Bloodstream infections in febrile neutropenic patients at a tertiary care center in Lebanon: a view of the past decade. Int J Infect Dis. 2007;11: 450–3 doi: 10.1016/j.ijid.2006.12.008 17337226

31. Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie TA, van de Wetering MD, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012; 1: CD004386. doi: 10.1002/14651858.CD004386.pub3 22258955

32. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005; 42: 979–95.

33. Gafter-Gvili A, Fraser A, Paul M, Van de Wetering M, Kremer L, Leibovici L. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy (Review). Cochrane Database Syst Rev. 2005;4:CD004386.

34. Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother. 2007; 59: 5–22. doi: 10.1093/jac/dkl425 17077101

35. Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997; 25: 247–59. doi: 10.1086/514550 9332520

36. Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et. Al. ESMO Guidelines Committee. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016; 27(suppl 5):v111–v118. doi: 10.1093/annonc/mdw325 27664247

37. Feld R. Bloodstream infections in cancer patients with febrile neutropenia. Int J Antimicrob Agents. 2008; 32 Suppl 1: S30–3.

38. Villafuerte-Gutierrez P, Villalon L, Losa JE, Henriquez-Camacho C. Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update. Adv Hematol. 2014; 986938. doi: 10.1155/2014/986938 25525436

39. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et. al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–205. doi: 10.1200/JCO.2006.06.4451 16682719

40. Smith T. J., Bohlke K., Lyman G. H., Carson K. R., Crawford J., Cross S. J. et al. American Society of Clinical Oncology. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33:3199–212. doi: 10.1200/JCO.2015.62.3488 26169616

41. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, et al. American Society of Clinical Oncology. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000; 18: 3558–85.

42. Horita N, Shibata Y, Watanabe H, Namkoong H, Kaneko T. Comparison of antipseudomonal β-lactams for febrile neutropenia empiric therapy: systematic review and network meta-analysis. Clin Microbiol Infect. 2017;23:723–729. doi: 10.1016/j.cmi.2017.03.024 28377312

43. Cozzi JA. Guías de recomendaciones sobre diagnóstico, tratamiento y prevención de infecciones en pacientes con cáncer. Consenso de la Sociedad Argentina de Infectología, Comisión de Infecciones en el Paciente Neoplásico y Trasplantado de Médula Ósea, 2008.

44. Baskaran ND, Gan GG, Adeeba K, Sam IC. Bacteremia in patients with febrile neutropenia after chemotherapy at a university medical center in Malaysia. Int J Infect Dis 2007; 6: 513–17.

45. Anoshirvani AA, Zarinfar N, Rafiee M, Zamani Z. Effect of Combination Therapy of Ceftazidime/Amikacin and Monotherapy with Imipenem on the Treatment of Fever and Neutropenia in Patients with Cancers. Open Access Maced J Med Sci. 2018;6:1423–1430 doi: 10.3889/oamjms.2018.310 30159069

46. Heinz WJ, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Cornely OA, Einsele H, et al. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol. 2017;96:1775–1792. doi: 10.1007/s00277-017-3098-3 28856437

47. Schmidt-Hieber M, Teschner D, Maschmeyer G, Schalk E. Management of febrile neutropenia in special consideration of the role of antimicrobial de-escalation. Expert Rev Anti Infect Ther. 2019 Jan 28. doi: 10.1080/14787210.2019.1573670 30686067

48. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol. 2000; 110: 273–84. doi: 10.1046/j.1365-2141.2000.02014.x 10971382

A multicenter prospective study of 515 febrile neutropenia episodes in Argentina during a 5-year period

Souhrn

Klíčová slova:

Zdroje

PLOS One

Aktuální možnosti diagnostiky a léčby litiáz